Setoxaximab represents a highly specialized humanized monoclonal antibody specifically engineered to target the A subunit of Shiga toxin 2 (Stx2) with exceptional binding affinity, effectively facilitating the measurable neutralization of toxin-mediated cytotoxicity across various preclinical experimental models to evaluate the prevention of endothelial cell death and microvascular thrombosis during strictly monitored laboratory observation periods and functional cell viability assays.